Delisting risk
Jupiter Neurosciences
Develops CNS drug candidates and sells Nugevia longevity supplements.
$3.07
After-hours close−1.09 (−26.11%)
At close$4.16(−15.03%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$3.75 | −$5.06 | −34.9% |
| May 2026 | −$3.75 | −$4.39 | −17.0% |
| May 2026 | −$0.05 | −$0.06 | −20.0% |
| Apr 2026 | −$5.25 | −$5.61 | −6.9% |
The latest year is open to everyone — the 25 quarters behind it read with an account. Sign in | |||
| Apr 2026 | |||
| Dec 2025 | |||
| Nov 2025 | |||
| Aug 2025 | |||
| Aug 2025 | |||
| Jun 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Mar 2025 | |||
| Dec 2024 | |||
| Sep 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | −$3.75 | −$5.06 | −34.9% | $400.0K | $24.2K | −93.9% |
| May 21, 2026 | −$3.75 | −$4.39 | −17.0% | $400.0K | $18.7K | −95.3% |
| May 14, 2026 | −$0.05 | −$0.06 | −20.0% | $225.0K | $18.7K | −91.7% |
| Apr 3, 2026 | −$5.25 | −$5.61 | −6.9% | $75.0K | $21.8K | −70.9% |
The latest year is open to everyone — the 25 quarters behind it read with an account. Sign in | ||||||
| Apr 1, 2026 | ||||||
| Dec 22, 2025 | ||||||
| Nov 14, 2025 | ||||||
| Aug 21, 2025 | ||||||
| Aug 18, 2025 | ||||||
| Jun 27, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 31, 2025 | ||||||
| Mar 28, 2025 | ||||||
| Dec 23, 2024 | ||||||
| Sep 4, 2024 | ||||||
| Jun 30, 2024 | ||||||
| Mar 31, 2024 | ||||||
| Dec 31, 2023 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||